Douglas Vincent Faller - 06 Nov 2026 Form 4 Insider Report for Imunon, Inc. (IMNN)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
10 Nov 2026, 19:15:20 UTC
Prior SEC filing
27 Oct 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jeffrey W Church, Attorney in Fact for Douglas Faller
Filing notes and source

Key filing fact

Douglas Vincent Faller filed Form 4 for Imunon, Inc. (IMNN) on 10 Nov 2026.

Key facts

  • This page summarizes Douglas Vincent Faller's Form 4 filing for Imunon, Inc. (IMNN).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 10 Nov 2026, 19:15.

Change

  • Previous filing in this sequence was filed on 27 Oct 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002056033 Primary reporting owner

Faller Douglas Vincent

Relationship
Chief Medical Officer
Address
C/O IMUNON, INC., 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE
Signature
/s/ Jeffrey W Church, Attorney in Fact for Douglas Faller
Signature date
10 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMNN transaction

Common Stock

Award

Transaction value
Shares
+1,596
Change %
+2.1%
Price
$0.8450*
Shares after
76,356
Date
06 Nov 2026
Ownership
Direct
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

SEC remarks

Stock Grant (26,741 shares) Stock granted in lieu of cash for portion of base salary (1.092 shares)

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .